Recent Updates
Recently added Catalysts

bimatoprost formulation A

Phase 3

Idiopathic Eyelash Hypotrichosis | Small molecule | Other |AbbVie Inc.|Last Updated: Feb 10, 2015

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment464
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01698554Bimatoprost in the Treatment of Eyelash HypotrichosisPHASE3 COMPLETED 464Nov 1, 2012Mar 1, 2014Feb 10, 20154 United States, Russia +2
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Percentage of Participants With at Least a 1-Grade Increase (Improvement) From Baseline in the Investigator's Assessment of Overall Eyelash Prominence (GEA)
Baseline, Month 4

The investigator evaluated the overall eyelash prominence in both eyes using the GEA 4-point scale: 1= minimal, 2= moderate, 3= marked and 4= very marked. A 1-grade improvement in the GEA score from Baseline indicated improvement.

Secondary Endpoints
Change From Baseline in Upper Eyelash Length as Measured Using Digital Image Analysis (DIA)
Baseline, Month 4
Change From Baseline in Upper Eyelash Thickness/Fullness as Measured Using DIA
Baseline Month 4
Change From Baseline in Upper Eyelash Intensity (Darkness) as Measured Using DIA
Baseline, Month 4
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
bimatoprost formulation A solutionEXPERIMENTALBimatoprost formulation A solution single-dose vial applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
bimatoprost solution 0.03 %ACTIVE_COMPARATORBimatoprost solution 0.03 % (LATISSE®) multi-dose vial applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
vehicle of bimatoprost formulation A solutionPLACEBO_COMPARATORVehicle of bimatoprost formulation A solution single-dose vial applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
vehicle of bimatoprost solution 0.03 %PLACEBO_COMPARATORVehicle of bimatoprost solution 0.03 % multi-dose vial applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
Interventions
NameTypeDescription
bimatoprost formulation A solutionDRUGBimatoprost formulation A solution applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
bimatoprost solution 0.03 %DRUGBimatoprost solution 0.03 % (LATISSE®) applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
vehicle of bimatoprost formulation A solutionDRUGVehicle of bimatoprost formulation A solution applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
vehicle of bimatoprost solution 0.03 %DRUGVehicle of bimatoprost solution 0.03 % applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites4

Inclusion Criteria: -Male and female adult patients with eyelash hypotrichosis (inadequate eyelash growth). Exclusion Criteria: * Damage to eyelid area (scarring) that may prevent growth of eyelashes * Active eye diseases (glaucoma, uveitis, eye infections, chronic blepharitis or severe dry eye) ...

Countries:United StatesRussiaSwedenUnited Kingdom
Unlock Eligibility Criteria